首页> 外文OA文献 >Radiotherapy in Combination with Chimeric Antigen Receptor T Cell Therapy Is a Safe and Promising Approach in Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients with High Tumor Burden

【2h】

Radiotherapy in Combination with Chimeric Antigen Receptor T Cell Therapy Is a Safe and Promising Approach in Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients with High Tumor Burden

机译：放射疗法与嵌合抗原受体T细胞疗法的组合是一种安全和有希望的方法，具有高肿瘤负担的复发/难治性弥漫性大B细胞淋巴瘤患者

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
J. Zhu; X. Yin; S. Qin;
展开▼
作者单位

展开▼
年度 2019
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Radiotherapy in Combination with Chimeric Antigen Receptor T Cell Therapy Is a Safe and Promising Approach in Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients with High Tumor Burden [J] . Zhu J., Yin X., Qin S. International Journal of Radiation Oncology, Biology, Physics . 2019,第1Suppla期

机译：放射疗法与嵌合抗原受体T细胞疗法的组合是一种安全和有希望的方法，具有高肿瘤负担的复发/难治性弥漫性大B细胞淋巴瘤患者
2. Radiotherapy Priming Chimeric Antigen Receptor T Cell Therapy Is a Safe and Promising Approach in Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients with High Tumor Burden [J] . Qu Changju, Ping Nana, Wu Qian, Blood: The Journal of the American Society of Hematology . 2018,第NovaelaTreatmentAppr期

机译：放射治疗喷射嵌合抗原受体T细胞疗法是一种安全和有希望的方法，具有高肿瘤负担的复发/难治性弥漫性大B细胞淋巴瘤患者
3. Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden [J] . Qu Changju, Ping Nana, Kang Liqing, Journal of immunotherapy . 2020,第1期

机译：辐射灌注嵌合抗原受体T细胞治疗复发/难治性扩散大B细胞淋巴瘤具有高肿瘤负荷
4. Main Issues and Current Strategies in Enhancing the Efficacy of Chimeric Antigen Receptor T-Cell Therapy among Tumor Treatments [C] . Zhengting He International Conference on Frontiers of Biological Sciences and Engineering . 2020

机译：提高嵌合抗原受体T细胞治疗肿瘤治疗疗效的主要问题及目前策略
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma [O] . Yaqing Cao, Wenyi Lu, Rui Sun, 2007

机译：抗CD19嵌合抗原受体T细胞与Nivolumab组合可安全有效地治疗复发/难治性B细胞非霍奇金淋巴瘤
7. Impact and safety of chimeric antigen receptor T-cell therapy in older, vulnerable patients with relapsed/refractory large B-cell lymphoma [O] . Richard J. Lin, Stephanie M. Lobaugh, Martina Pennisi, 2020

机译：嵌合抗原受体T细胞疗法在复发/难治性大B细胞淋巴瘤中较旧的脆弱患者的影响和安全性

Radiotherapy in Combination with Chimeric Antigen Receptor T Cell Therapy Is a Safe and Promising Approach in Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients with High Tumor Burden

著录项

引文网络

相似文献

相关主题

期刊订阅